argenx SE (NASDAQ:ARGX) Stock Holdings Increased by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC raised its holdings in shares of argenx SE (NASDAQ:ARGX) by 5.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,805 shares of the company’s stock after buying an additional 94 shares during the period. Sequoia Financial Advisors LLC’s holdings in argenx were worth $1,110,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. Stifel Financial Corp boosted its stake in shares of argenx by 15.3% during the 3rd quarter. Stifel Financial Corp now owns 8,832 shares of the company’s stock worth $4,788,000 after acquiring an additional 1,170 shares in the last quarter. FMR LLC boosted its position in shares of argenx by 35.9% in the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company’s stock valued at $2,598,445,000 after purchasing an additional 1,265,486 shares during the period. Stephens Inc. AR purchased a new position in argenx in the 4th quarter worth about $310,000. Ritholtz Wealth Management raised its holdings in shares of argenx by 85.5% during the fourth quarter. Ritholtz Wealth Management now owns 898 shares of the company’s stock valued at $552,000 after acquiring an additional 414 shares during the period. Finally, Westfield Capital Management Co. LP acquired a new position in argenx in the 3rd quarter worth approximately $571,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on ARGX. Guggenheim increased their target price on argenx from $775.00 to $1,100.00 and gave the company a “buy” rating in a report on Monday, March 10th. Deutsche Bank Aktiengesellschaft raised argenx from a “sell” rating to a “hold” rating in a research note on Wednesday. Robert W. Baird increased their price target on shares of argenx from $650.00 to $680.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 4th. Citigroup reaffirmed an “outperform” rating on shares of argenx in a research report on Friday, February 28th. Finally, Oppenheimer lifted their target price on shares of argenx from $675.00 to $704.00 and gave the company an “outperform” rating in a research note on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, argenx currently has a consensus rating of “Moderate Buy” and an average target price of $687.00.

argenx Stock Up 4.1 %

Shares of ARGX stock opened at $604.96 on Friday. argenx SE has a 12 month low of $349.86 and a 12 month high of $678.21. The company has a market cap of $36.76 billion, a PE ratio of -687.45 and a beta of 0.59. The business’s 50 day moving average is $638.20 and its two-hundred day moving average is $596.33.

argenx (NASDAQ:ARGX) last posted its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.60. The business had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. As a group, equities analysts expect that argenx SE will post 3.13 EPS for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.